{
    "clinical_study": {
        "@rank": "149921", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive bryostatin 1 IV over 72 hours on days 1-3 followed by cisplatin IV over 1 hour on day 4. Treatment repeats every 3 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of bryostatin 1 and cisplatin in treating patients\n      who have metastatic or unresectable stomach cancer. Drugs used in chemotherapy use different\n      ways to stop tumor cells from dividing so they stop growing or die. Bryostatin 1 may\n      increase the effectiveness of cisplatin by making tumor cells more sensitive to the drug.\n      Combining cisplatin with bryostatin 1 may kill more tumor cells."
        }, 
        "brief_title": "Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer", 
        "condition": [
            "Stage III Gastric Cancer", 
            "Stage IV Gastric Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the response rate and survival in patients with metastatic or unresectable\n      carcinoma of the stomach treated with bryostatin 1 and cisplatin.\n\n      II. Determine the toxic effects of this regimen in these patients. III. Determine the\n      molecular determinants of response to this regimen in these patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive bryostatin 1 IV over 72 hours on days 1-3 followed by cisplatin IV over 1\n      hour on day 4. Treatment repeats every 3 weeks for a minimum of 2 courses in the absence of\n      disease progression or unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of metastatic or unresectable carcinoma of the stomach\n\n          -  Measurable disease\n\n          -  No brain metastasis\n\n          -  Performance status - Karnofsky 70-100%\n\n          -  More than 3 months\n\n          -  WBC at least 3,000/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  Hemoglobin at least 10 g/dL\n\n          -  No history of any bleeding disorders\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  Transaminases no greater than 2 times normal\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n          -  Creatinine clearance at least 60 mL/min\n\n          -  No history of peptic ulceration or gastrointestinal bleeding\n\n          -  No active infection\n\n          -  No seizure disorder\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  HIV negative\n\n          -  No other serious concurrent illness that would preclude study entry\n\n          -  No medical, social, or psychological factors that would preclude study entry\n\n          -  No prior chemotherapy\n\n          -  No prior radiotherapy\n\n          -  More than 4 weeks since prior major surgery\n\n          -  Prior incomplete resection allowed\n\n          -  No other prior antitumor treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006389", 
            "org_study_id": "NCI-2012-02361", 
            "secondary_id": [
                "NCI-2012-02361", 
                "CHNMC-PHII-22", 
                "CDR0000068267", 
                "NCI-T99-0040", 
                "PHII-22 (USC 3S-00-1)", 
                "T99-0040", 
                "N01CM17101"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment", 
                "description": "Given IV", 
                "intervention_name": "bryostatin 1", 
                "intervention_type": "Drug", 
                "other_name": [
                    "B705008K112", 
                    "BRYO", 
                    "Bryostatin"
                ]
            }, 
            {
                "arm_group_label": "Treatment", 
                "description": "Given IV", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CACP", 
                    "CDDP", 
                    "CPDD", 
                    "DDP"
                ]
            }, 
            {
                "arm_group_label": "Treatment", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bryostatin 1", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90033-0804"
                }, 
                "name": "University of Southern California"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Combination Trial of Bryostatin-1 and Cisplatin in the Treatment of Metastatic Gastric Cancer", 
        "overall_official": {
            "affiliation": "University of Southern California", 
            "last_name": "Heinz-Josef Lenz", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Associated exact 95% confidence intervals will be calculated.", 
                "measure": "Observed response rate, calculated as the percent of evaluable patients whose best response is a CR or PR", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 years"
            }, 
            {
                "description": "Will be estimated using the product-limit method of Kaplan and Meier.", 
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 years"
            }, 
            {
                "description": "Will be estimated using the product-limit method of Kaplan and Meier.", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 years"
            }, 
            {
                "description": "Will be estimated using the product-limit method of Kaplan and Meier.", 
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 years"
            }, 
            {
                "description": "Toxicity information recorded will include the type, severity, time of onset, time of resolution, and the probably association with the study regimen. Tables will be constructed to summarize the observed incidence by severity and type of toxicity.", 
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 9 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006389"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 2000", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }, 
    "geocoordinates": {
        "University of Southern California": "34.052 -118.244"
    }
}